2.79
price down icon3.79%   -0.11
after-market Dopo l'orario di chiusura: 2.80 0.010 +0.36%
loading
Precedente Chiudi:
$2.90
Aprire:
$2.9
Volume 24 ore:
111.51K
Relative Volume:
0.46
Capitalizzazione di mercato:
$77.78M
Reddito:
-
Utile/perdita netta:
$-14.14M
Rapporto P/E:
-3.0326
EPS:
-0.92
Flusso di cassa netto:
$-12.64M
1 W Prestazione:
-4.45%
1M Prestazione:
+24.55%
6M Prestazione:
+36.10%
1 anno Prestazione:
+35.44%
Intervallo 1D:
Value
$2.74
$2.90
Intervallo di 1 settimana:
Value
$2.74
$3.0993
Portata 52W:
Value
$1.26
$3.12

Immix Biopharma Inc Stock (IMMX) Company Profile

Name
Nome
Immix Biopharma Inc
Name
Telefono
(888) 958-1084
Name
Indirizzo
11400 WEST OLYMPIC BLVD., LOS ANGELES
Name
Dipendente
21
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-09
Name
Ultimi documenti SEC
Name
IMMX's Discussions on Twitter

Confronta IMMX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
IMMX
Immix Biopharma Inc
2.79 79.45M 0 -14.14M -12.64M -0.92
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Immix Biopharma Inc Borsa (IMMX) Ultime notizie

pulisher
Jul 24, 2025

Is Immix Biopharma Inc. stock a growth or value playFree Predictions - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Immix Biopharma Inc. stockFree Stock Market Knowledge Sharing - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Immix Biopharma Inc. a good long term investmentRecord-setting profit potential - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Immix Biopharma Inc. Stock Analysis and ForecastUnrivaled growth potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Immix Biopharma Inc. stock priceTremendous wealth creation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 17, 2025

What makes Immix Biopharma Inc. stock price move sharplyFree AI-Powered Stock Predictions - Newser

Jul 17, 2025
pulisher
Jul 16, 2025

Why Immix Biopharma Inc. stock attracts strong analyst attentionHigh Yield Opportunities - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

How Immix Biopharma Inc. stock performs during market volatilityBreakout Level Watch - Newser

Jul 15, 2025
pulisher
Jul 12, 2025

ImmixBio reports no neurotoxicity in CAR-T therapy for AL amyloidosis - Investing.com Nigeria

Jul 12, 2025
pulisher
Jul 11, 2025

ImmixBio reports no neurotoxicity in CAR-T therapy for AL amyloidosis By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Immix Biopharma Says NXC-201 Safety Profile Shows Absence of Neurotoxicity in Low-Volume Disease - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission - Nasdaq

Jul 11, 2025
pulisher
Jul 11, 2025

Revolutionary CAR-T Safety Data: IMMX Reports Zero Neurotoxicity in Rare Disease Treatment - Stock Titan

Jul 11, 2025
pulisher
Jul 09, 2025

Immix Biopharma (NASDAQ:IMMX) Stock Price Up 1.5% – Here’s Why - Defense World

Jul 09, 2025
pulisher
Jul 08, 2025

Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Nigeria

Jul 08, 2025
pulisher
Jul 08, 2025

Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating - Investing.com

Jul 08, 2025
pulisher
Jul 07, 2025

Immix Biopharma Expands NEXICART-2 Trial Sites Nationwide, Progressing Towards Biologics License Application for Cell Therapy in AL Amyloidosis - Nasdaq

Jul 07, 2025
pulisher
Jul 07, 2025

Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

Breakthrough Cell Therapy for AL Amyloidosis Accelerates Toward FDA Approval with 18 Trial Sites - Stock Titan

Jul 07, 2025
pulisher
Jun 28, 2025

Immix Biopharma (NASDAQ:IMMX) Upgraded by Wall Street Zen to Hold Rating - Defense World

Jun 28, 2025
pulisher
Jun 23, 2025

Immix Biopharma Holds Annual Meeting, Elects Directors - TipRanks

Jun 23, 2025
pulisher
Jun 20, 2025

Immix Biopharma CEO Rachman buys $4998 in shares - Investing.com

Jun 20, 2025
pulisher
Jun 10, 2025

Jane Street Group LLC Invests $39,000 in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN

Jun 10, 2025
pulisher
Jun 07, 2025

Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Jun 07, 2025
pulisher
Jun 07, 2025

Q3 EPS Estimates for Immix Biopharma Raised by HC Wainwright - Defense World

Jun 07, 2025

Immix Biopharma Inc Azioni (IMMX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):